IQVIA, Boehringer Ingelheim Partner on Global Commercial Data Transformation

IQVIA, a global provider of clinical research services, healthcare intelligence, and commercial insights, has entered into a strategic long-term collaboration with Boehringer Ingelheim to modernize and harmonize the pharmaceutical company’s global commercial data ecosystem. Under the agreement, Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) platform as a central accelerator for its commercial data transformation strategy.

The collaboration is designed to support Boehringer Ingelheim’s ambition to scale advanced analytics and data-driven decision-making across its global operations. By leveraging IQVIA’s industry-leading global data model, the partnership aims to unify commercial data from multiple sources and regions into a single, harmonized platform that can be accessed consistently across therapeutic areas and markets.

At the core of the agreement is the integration of IQVIA’s DaaS+ technology into Boehringer Ingelheim’s existing cloud infrastructure. The platform enables seamless ingestion, standardization, and management of global commercial datasets, helping reduce complexity and improve operational efficiency. This unified approach is expected to support a wide range of advanced analytics use cases, from performance tracking and forecasting to more sophisticated AI-driven insights.

Justin Gale, Global Head of Data Excellence at Boehringer Ingelheim, said the company sees significant potential in working with IQVIA’s DaaS+ platform. He noted that the ability to integrate global commercial data into a single, cloud-based environment could drive efficiencies across data operations, while also enabling innovative analytics applications that support more informed and timely decision-making.

The collaboration will play a key role in supporting Boehringer Ingelheim’s upcoming product launches, as well as enhancing the performance of existing brands. The harmonized data foundation will provide standardized reporting across markets, brands, and franchises in 59 countries. This includes capabilities such as global product mastering, streamlined data governance, and simplified access to both internal and IQVIA-sourced data.

For IQVIA, the partnership reinforces its position as a strategic data and analytics partner to leading pharmaceutical companies navigating increasingly complex global markets. Tom Baker, Senior Vice President of Global Data, Technologies and Advisory Services at IQVIA, said the collaboration will help Boehringer Ingelheim establish a robust global data foundation that supports faster, data-informed decisions and accelerates the company’s transition toward AI-powered analytics.

As life sciences organizations place growing emphasis on real-time insights, scalability, and advanced analytics, the IQVIA–Boehringer Ingelheim collaboration reflects a broader industry shift toward platform-based data strategies. By standardizing commercial data at a global level, the partnership is expected to improve visibility, consistency, and agility, enabling Boehringer Ingelheim to respond more effectively to evolving market dynamics and patient needs.